NCT07172360View on ClinicalTrials.gov

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2027

Conditions
Active Ankylosing Spondylitis
Interventions
DRUG

VC005 tablets

VC005 groups repeat administration for 48 weeks

DRUG

VC005 Tablets Placebo

VC005 placebo groups repeat administration for 48 weeks

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Jiangsu vcare pharmaceutical technology co., LTD

INDUSTRY